Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Number To Know…2,000

Executive Summary

Up to 2,000 patients will be enrolled in Cardiovascular Systems' US pivotal study of its artherectomy system.

2,000 is the number of patients Cardiovascular Systems plans to enroll in its ECLIPSE Coronary Clinical Trial utilizing the Diamondback 360 Coronary Orbital Artherectomy System (OAS). The ECLIPSE study recently enrolled its first subject at St. Francis Hospital in Roslyn, New York. Half the participants will receive orbital atherectomy prior to DES implantation, while the other half will receive conventional angioplasty, including specialty balloons, followed by DES implantation. The trial is powered to demonstrate differences in the primary endpoints of post-procedural minimal cross-sectional area (assessed by intravascular imaging in a subset of up to 400 patients) as well as in the clinical outcome of target vessel failure at one year. ECLIPSE will also evaluate key health economic outcomes.

Meddevicetracker subscribers can access a full analysis of Cardiovascular System's product portfolio including the clinical and regulatory status of the Diamondback 360 Coronary Orbital Artherectomy System here.

Not a subscriber, click here to request your free demo.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts